35661-60-0
Chemical Structure
Fmoc-leucine
Synonym(s): N-FMOC-leucine; NPC 15199; NSC 334290
- CAS. Nr.: 35661-60-0
- Formula:C21H23NO4
- Molecular Weight:353.42
IUPAC Name: (((9H-fluoren-9-yl)methoxy)carbonyl)-L-leucine
InChIKey: CBPJQFCAFFNICX-IBGZPJMESA-N
SMILES: CC(C)C[C@@H](C(O)=O)NC(OCC1C2=C(C3=C1C=CC=C3)C=CC=C2)=O
Biological Activity: Fmoc-Leucine (N-FMOC-leucine) is an anti-inflammatory agent that not only promotes extracellular Ca2+ influx but also facilitates intracellular Ca2+ release. Fmoc-Leucine is a selective ligand for PPARγ (Ki = 15 μM), exhibiting insulin-sensitizing effects but with weak fatogenic activity. Fmoc-Leucine exhibits unique self-assembly properties and can form transient gels, stable gels, or crystals/2D sheets through different pathways. Fmoc-Leucine can be used in the research of diabetes, colitis, and bladder cancer[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fmoc-leucine | 99.9% | Fmoc-Leucine (N-FMOC-leucine) is an anti-inflammatory agent that not only promotes extracellular Ca2+ influx but also facilitates intracellular Ca2+ release. Fmoc-Leucine is a selective ligand for PPARγ (Ki = 15 μM), exhibiting insulin-sensitizing effects but with weak fatogenic activity. Fmoc-Leucine exhibits unique self-assembly properties and can form transient gels, stable gels, or crystals/2D sheets through different pathways. Fmoc-Leucine can be used in the research of diabetes, colitis, and bladder cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine (Standard) | ≥98% | Fmoc-leucine (Standard) is the analytical standard of Fmoc-leucine (HY-101064). This product is intended for research and analytical applications. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine-d10 | 99.40% | Fmoc-leucine-d10 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine-15N | 98.5% | Fmoc-leucine-15N is a 15N-labeled and 15N-labled Fmoc-leucine (HY-101064). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine-13C6,15N | 95.12% | Fmoc-leucine-13C6,15N is a 15N-labeled and 13C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine-13C | 99.90% | Fmoc-leucine-13C is a 13C-labeled Boc-GlycineFmoc-leucine (HY-101064). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine-d3 | 99.25% | Fmoc-leucine-d3 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Rocchi S, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell. 2001 Oct;8(4):737-47. [Content Brief]
- [2]. Paul S, et al. Complex Pathways Drive Pluripotent Fmoc-Leucine Self-Assemblies. Angew Chem Int Ed Engl. 2024 Sep 9;63(37):e202406220. [Content Brief]
- [3]. Jan CR, Yu CC, Huang JK. NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells. Chin J Physiol. 2000 Mar 31;43(1):29-33. [Content Brief]
- [4]. Jan CR, et al. Effect of NPC-15199 on Ca2+ levels in renal tubular cells. Chin J Physiol. 2002 Sep 30;45(3):117-22. Erratum in: Chin J Physiol. 2003 Dec 31;45(4):200. [Content Brief]
